TY - JOUR
T1 - Vascular endothelial growth factor targeted therapy in the perioperative setting
T2 - Implications for patient care
AU - Bose, Debashish
AU - Meric-Bernstam, Funda
AU - Hofstetter, Wayne
AU - Reardon, David A.
AU - Flaherty, Keith T.
AU - Ellis, Lee M.
N1 - Funding Information:
FM-B has received honoraria from Novartis and Sysmex. DAR had consulted for Merck, Genentech, Merck KGaA, Adnexus, and Glaxo Smith Kline (GSK), has acted as a speaker for Genentech and Schering Plough, and has received honoraria from Merck, Genentech, Merck KGaA, Schering Plough, Bayer, and GSK. KTF has consulted for Genentech and Bayer/Onyx. LEM has consulted for and received honoraria from Genentech/Roche, Amgen, AstraZeneca, Pfizer, and Regeneron and received research funding from Sanofi-Aventis and ImClone Systems. All other authors declared no conflicts of interest.
PY - 2010/4
Y1 - 2010/4
N2 - Vascular endothelial growth factor (VEGF) targeted therapy, either alone or in combination with chemotherapy, has become the standard of care in several solid tumours, including colorectal cancer, renal-cell carcinoma, breast cancer, non-small-cell lung cancer, and glioblastoma. VEGF is crucial in the process of angiogenesis and wound healing and, thus, its inhibition has the potential to affect wound healing in patients undergoing surgery. In this review, we summarise the data available on the use of VEGF-targeted therapies, and their effect on perioperative wound complications. Surgery in patients receiving VEGF-targeted therapies seems to be safe when an appropriate interval of time is allowed between surgical procedures and treatment. Recommendations regarding this interval are provided in a disease and agent site-specific manner. We also discuss complications arising from the use of VEGF-directed therapies that might require surgical intervention and the considerations important in their management. At this juncture, safety data on the use of VEGF-targeted therapies in the perioperative period are sparse, and investigators are urged to continue to study this issue prospectively in current and future clinical trials to establish firm guidelines.
AB - Vascular endothelial growth factor (VEGF) targeted therapy, either alone or in combination with chemotherapy, has become the standard of care in several solid tumours, including colorectal cancer, renal-cell carcinoma, breast cancer, non-small-cell lung cancer, and glioblastoma. VEGF is crucial in the process of angiogenesis and wound healing and, thus, its inhibition has the potential to affect wound healing in patients undergoing surgery. In this review, we summarise the data available on the use of VEGF-targeted therapies, and their effect on perioperative wound complications. Surgery in patients receiving VEGF-targeted therapies seems to be safe when an appropriate interval of time is allowed between surgical procedures and treatment. Recommendations regarding this interval are provided in a disease and agent site-specific manner. We also discuss complications arising from the use of VEGF-directed therapies that might require surgical intervention and the considerations important in their management. At this juncture, safety data on the use of VEGF-targeted therapies in the perioperative period are sparse, and investigators are urged to continue to study this issue prospectively in current and future clinical trials to establish firm guidelines.
UR - http://www.scopus.com/inward/record.url?scp=77950339501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950339501&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(09)70341-9
DO - 10.1016/S1470-2045(09)70341-9
M3 - Review article
C2 - 20171141
AN - SCOPUS:77950339501
SN - 1470-2045
VL - 11
SP - 373
EP - 382
JO - The lancet oncology
JF - The lancet oncology
IS - 4
ER -